Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH): 1 pipeline candidate · ~2 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.9 months
D/E 2.53 · 0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Shuttle Pharmaceuticals Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.5M
Cash
$1.1M
Quarterly Burn
$2.4M
Runway
1.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| ropidoxuridine | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$46K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 46,217 | $31K |
| boothbay fund management, llc | 20,360 | $14K |
| kelleher financial advisors | 600 | $407 |
| morgan stanley | 27 | $18 |
Frequently asked questions
How many drug candidates are in Shuttle Pharmaceuticals Holdings, Inc.'s pipeline?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Shuttle Pharmaceuticals Holdings, Inc.'s lead drug candidate?
Shuttle Pharmaceuticals Holdings, Inc.'s most advanced tracked candidate is ropidoxuridine (Phase 2) for Glioblastoma, IDH-wildtype.
What is Shuttle Pharmaceuticals Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Shuttle Pharmaceuticals Holdings, Inc. has approximately 1.9 months of cash runway.
What is Shuttle Pharmaceuticals Holdings, Inc.'s market capitalization?
Shuttle Pharmaceuticals Holdings, Inc.'s market capitalization is approximately $2.5M.
Who is the CEO of Shuttle Pharmaceuticals Holdings, Inc.?
Mr. Christopher Robert Cooper BBA, M.B.A. is the chief executive officer of Shuttle Pharmaceuticals Holdings, Inc. (SHPH).
Get the full picture on Shuttle Pharmaceuticals Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.